BUSINESS

Teva Takeda Yakuhin Applies for Pediatric Use for Blopress Based on Information in Public Domain

December 7, 2018
Teva Takeda Yakuhin announced on December 6 that it has applied for a pediatric indication based on information in the public domain for the angiotensin receptor blocker (ARB) Blopress Tablets (candesartan). The Japanese Society of Pediatric Cardiology and Cardiac Surgery…

To read the full story

BUSINESS

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…